Form 4: Incyte Corp Executive Vice President Granted Stock Options

Incyte Corp's Executive Vice President, Vijay K Iyengar, was granted 14,772 stock options on January 17, 2025, which vest over a three-year period.

Summary

• Vijay K Iyengar, an Executive Vice President at Incyte Corp, was granted 14,772 employee stock options on January 17, 2025.
• The options have an exercise price of $71.93.
• The options vest in 37 installments, with 25% vesting on July 15, 2025, and the remainder vesting monthly over three years.
• The options expire on January 16, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There is no indication of any negative or unexpected events.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The stock options will vest over a three-year period, incentivizing the executive to contribute to the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the pharmaceutical and biotechnology industries.
• The vesting schedule of 25% initially and the remainder over three years is a typical vesting structure.
• Companies like Regeneron, Gilead, and Vertex often use similar stock option plans to incentivize their executives.

Stakeholder Impact

• Shareholders may view this positively as it aligns executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, vesting, Incyte Corp, equity